Spironolactone
Treatment for Polycystic Ovary Syndrome
Typical Dosage: 50-100mg daily
Effectiveness
60%
Safety Score
65%
Clinical Trials
9
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
50-100mg daily
Time to Effect
3-6 months
Treatment Duration
long-term
Evidence Quality
MODERATENumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$75
Side Effect Mgmt:$20
Total Annual:$170
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.12
Outcome-Based Costs
Cost per Responder
$212
Spironolactone Outcomes
for Polycystic Ovary Syndrome
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+80%
Common Side Effects
Menstrual irregularities
+15%
Dizziness
+8%
Breast tenderness
+7%
Hyperkalemia
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Spironolactone in Polycystic Ovary Syndrome
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
NCT04723862RECRUITINGEARLY_PHASE1
32 participants
INTERVENTIONAL
Charlottesville, United States
Started: Nov 12, 2021
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
NCT03068910RECRUITINGEARLY_PHASE1
32 participants
INTERVENTIONAL
Charlottesville, United States
Started: Jul 21, 2016
Completed Clinical Trials
4 completed trials for Spironolactone in Polycystic Ovary Syndrome
Spironolactone Plus Metformin in Polycystic Ovary Syndrome
NCT01526616COMPLETEDNA
56 participants
INTERVENTIONAL
Started: May 1, 2010
Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
NCT02689843COMPLETEDEARLY_PHASE1
90 participants
INTERVENTIONAL
Shiraz, Iran
Started: Feb 1, 2018
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women
NCT00842140COMPLETEDNA
75 participants
INTERVENTIONAL
Ribeirão Preto, Brazil
Started: Feb 1, 2006
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
NCT00004311COMPLETEDPHASE2
INTERVENTIONAL
Started: Jul 1, 1989